EZH2 and neoplasm: Notably, EZH2 also inhibits the expression of endogenous retroviruses (ERVs) through H3K27me3 deposition, blocks the activation of the cGAS-STING signaling pathway, and inhibits the production of type I interferon and its downstream T-cell initiation process, thereby enhancing the immune escape ability of tumor cells (79, 80).